Hijacking the MDM2 E3 Ligase with Novel BRD4-Targeting Proteolysis-Targeting Chimeras in Pancreatic Cancer Cells
- PMID: 40317844
- PMCID: PMC12247027
- DOI: 10.1002/cbic.202500133
Hijacking the MDM2 E3 Ligase with Novel BRD4-Targeting Proteolysis-Targeting Chimeras in Pancreatic Cancer Cells
Abstract
The phenotypic effect induced by a Proteolysis-Targeting Chimera (PROTAC) can depend on several factors, including the E3 ligase recruited. For the discovery of a first-in-class PROTAC for a target of interest, the E3 ligases commonly hijacked remain the Von Hippel-Lindau (VHL) and Cereblon (CRBN) since potent and accessible ligands are readily available to recruit them. Mouse double minute 2 (MDM2) E3 ligase stands out because it regulates p53 levels to maintain cellular homeostasis. However, the synthesis of the most potent MDM2 ligands remains very complex. Herein, the discovery of novel MDM2-recruiting PROTACs incorporating rac-Nutlin-3 as a ligand with an easier synthetic tractability is reported, further demonstrating its potential in this technology. The most promising degrader, PROTAC 3, showed preferential degradation of the BRD4 short isoform (BRD4 S) and c-Myc compared with MZ1, a validated VHL-based PROTAC.
Keywords: BRD4; HDM2; MDM2; MIA PaCa‐2; PROTACs; pancreatic cancer; targeted protein degradation.
© 2025 The Author(s). ChemBioChem published by Wiley‐VCH GmbH.
Conflict of interest statement
The authors declare no conflict of interest.
Figures




Similar articles
-
Tumor-targeted PROTAC prodrug nanoplatform enables precise protein degradation and combination cancer therapy.Acta Pharmacol Sin. 2024 Aug;45(8):1740-1751. doi: 10.1038/s41401-024-01266-z. Epub 2024 Apr 12. Acta Pharmacol Sin. 2024. PMID: 38609561 Free PMC article.
-
Unveiling New Triazoloquinoxaline-Based PROTACs Designed for the Selective Degradation of the ncBAF Chromatin Remodeling Subunit BRD9.Chemistry. 2025 Jun 17;31(34):e202404218. doi: 10.1002/chem.202404218. Epub 2025 May 20. Chemistry. 2025. PMID: 40343767 Free PMC article.
-
Synthesis and Application of BRD4-Targeting ByeTACs (Bypassing E-Ligase Targeting Chimeras).Curr Protoc. 2025 Aug;5(8):e70196. doi: 10.1002/cpz1.70196. Curr Protoc. 2025. PMID: 40788235
-
Advances in KEAP1-based PROTACs as emerging therapeutic modalities: Structural basis and progress.Redox Biol. 2025 Sep;85:103781. doi: 10.1016/j.redox.2025.103781. Epub 2025 Jul 21. Redox Biol. 2025. PMID: 40714402 Free PMC article. Review.
-
PROteolysis TArgeting Chimera (PROTAC) Estrogen Receptor Degraders for Treatment of Estrogen Receptor-Positive Advanced Breast Cancer.Target Oncol. 2025 May;20(3):431-444. doi: 10.1007/s11523-025-01137-5. Epub 2025 May 6. Target Oncol. 2025. PMID: 40327300 Free PMC article. Review.
References
-
- Brown D. G., Wobst H. J., J. Med. Chem. 2021, 64, 2312. - PubMed
-
- Vetma V., O’Connor S., Ciulli A., Annu. Rev. Cancer Biol. 2024,. 9, 119.
-
- Bashore C., Prakash S., Johnson M. C., Conrad R. J., Kekessie I. A., Scales S. J., Ishisoko N., Kleinheinz T., Liu P. S., Popovych N., Wecksler A. T., Zhou L., Tam C., Zilberleyb I., Srinivasan R., Blake R. A., Song A., Staben S. T., Zhang Y., Arnott D., Fairbrother W. J., Foster S. A., Wertz I. E., Ciferri C., Dueber E. C., Nat. Chem. Biol. 2023, 19, 55. - PMC - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous